Short answer
Insmed Incorporated (INSM) filed its Q1 2025 10-Q quarterly report on May 8, 2025 for the quarter ended Mar 31, 2025. Quarterly revenue was $93M (up 22.9% year over year) with net income of −$257M.
Q1 2025 key financials · XBRL
- Revenue
- $93M
- +22.9% YoY
- Net income
- −$257M
- −63.3% YoY
- Operating margin
- -267.3%
- EPS (diluted)
- −$1.42
- −34.0% YoY
Source: XBRL data from the Insmed Incorporated (INSM) Q1 2025 10-Q on SEC EDGAR. USD.
Insmed Incorporated Q1 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No new or updated risk factors disclosed this quarter compared to 10-K filing
- Continued regulatory risk from FDA approval delays impacting product launch timing and revenue realization
- Competitive risk from emerging therapies targeting same rare diseases could reduce market share near-term
- Operational risk from manufacturing complexities for biologics may constrain supply and affect delivery schedules
- Financial risk includes reliance on limited cash reserves and need for capital raises to fund ongoing R&D programs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Insmed Incorporated quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.